|MDACC Study No:||2005-0726 (clinicaltrials.gov NCT No: NCT00475020)|
|Title:||Allogeneic stem cell transplantation for myelofibrosis and myelodysplastic syndrome using reduced intensity busulfan and fludarabine conditioning.|
|Principal Investigator:||Uday Popat|
|Treatment Agent:||Busulfan; Fludarabine; Thymoglobulin|
|Study Description:||The goal of this clinical research study is to learn if using a combination of |
fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control
myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow
or blood stem cell transplant. The safety of these drugs will also be studied.